Stock Report

All about this stock under one free report Last Updated: 24-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Asston Pharmaceuticals Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

BSE: 544445

₹100.15

up-down-arrow ₹-1.85 (-1.81%)

As on 23-Sep-2026IST

Market cap

info icon

₹109 Cr

Revenue (TTM)

info icon

₹25 Cr

P/E Ratio

info icon

28.3

P/B Ratio

info icon

1.7

Div. Yield

info icon

0 %

Edit peer-selector-edit
Asston Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 109 37,585 28,859 16,982 16,312
Revenue (₹ Cr)
 25 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 4.33 1,018.97 497.77 603.02 270.18
Net Margin (%)
 16.89 10.47 20.72 22.63 23.29
RoE (%)
 50.56 21.30 28.49 19.61 14.45
Price to Earnings
 28.31 37.16 57.98 28.16 59.23
Price-To-Book
 1.66 7.19 14.28 4.87 7.87

Income Statement (₹ Cr)

Asston Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
25.04 7,896.00 1,476.84 2,386.88 1,200.09
Total Income arrow
25.61 7,968.78 1,497.35 2,421.45 1,244.53
Total Expenditure arrow
18.88 6,427.14 1,153.58 1,704.30 693.24
EBITDA arrow
6.16 1,468.85 323.26 682.58 506.84
Depreciation arrow
0.08 384.13 65.55 60.61 54.37
EBIT arrow
6.08 1,084.73 257.71 621.98 452.47
Interest arrow
0.95 175.78 8.30 2.41 1.04
Other Income arrow
0.57 72.79 20.51 34.57 44.45
Exceptional Items arrow
-- -10.38 76.40 -- --
Profit before Tax arrow
5.70 971.35 346.33 654.13 494.55
Provision for Tax arrow
1.37 263.88 86.22 168.50 122.91
Profit after Tax arrow
4.33 707.47 260.11 485.63 371.64

Liabilities (₹ Cr)

Asston Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
10.72 4,446.19 1,524.81 2,817.37 1,812.72
Minority Interest arrow
-- 195.37 -- -- --
Non-Current Liabilities arrow
2.39 811.91 189.39 466.05 37.47
Current Liabilities arrow
14.99 2,668.27 465.69 470.16 184.06
Total Liabilities arrow
28.12 8,121.73 2,179.88 3,753.59 2,034.25

Assets (₹ Cr)

Asston Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
1.08 3,565.87 1,040.38 1,418.43 899.01
Current Assets arrow
27.02 4,555.86 1,139.50 2,335.16 1,135.24
Total Assets arrow
28.12 8,121.73 2,179.88 3,753.59 2,034.25
Total Debt* arrow
7.26 731.70 136.01 0.00 0.38
Net Current Assets arrow
12.03 1,887.59 673.81 1,865.00 951.18
Contingent Liabilities arrow
-- 393.94 8.97 4.82 3.91

Cashflow (₹ Cr)

Asston Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
-0.16 851.71 317.40 391.52 244.52
Cash Flow from Investing Activities arrow
0.87 -94.00 -298.16 -615.65 -159.99
Cash from Financing Activities arrow
-0.51 -813.96 24.96 -6.23 -98.77
Net Cash Inflow / Outflow arrow
0.19 -56.25 44.21 -230.35 -14.24

Ratios

Profitability Ratios

 Asston Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
42.64 22.49 23.45 25.50 29.62
ROE (%) arrow
50.56 19.19 18.54 18.94 22.26
ROA (%) arrow
17.89 8.94 12.97 13.34 19.90
EBIT Margin (%) arrow
26.88 19.52 23.28 30.05 45.94
Net Margin (%) arrow
16.89 8.88 17.37 20.06 29.86
Cash Profit Margin (%) arrow
17.60 13.61 22.05 22.79 35.50

Growth Ratios

 Asston Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
60.65 18.59 -5.24 4.54 18.01
EBIT Growth (%) arrow
140.32 19.81 -27.65 4.50 18.31
Net Profit Growth (%) arrow
217.95 34.10 -13.32 3.13 20.62
EPS Growth (%) arrow
217.94 30.75 -13.32 3.12 20.62
Book Value Growth (%) arrow
67.66 50.94 18.89 20.94 18.74

Valuation Ratios

 Asston Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
0.00 29.84 59.57 27.24 47.19
Price / Book Value arrow
0.00 4.58 10.17 4.71 9.67
Dividend Yield (%) arrow
-- 0.28 0.10 0.46 0.64
EV/EBITDA arrow
1.98 13.55 44.72 18.35 31.81
Market Cap (₹ Cr) arrow
0.00 20,327.45 15,494.53 13,228.83 17,537.35

Solvency Ratios

 Asston Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.68 0.17 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.35 0.11 -- -- 0.00
Current Ratio arrow
1.80 1.71 2.45 4.97 6.17
Quick Ratio arrow
1.75 0.98 1.62 3.53 4.87
Interest Coverage arrow
7.00 6.53 42.74 271.97 475.76

Operating Efficiency Ratios

 Asston Pharmaceuticals Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
98.04 25.36 21.38 40.63 43.47
Asset Turnover arrow
1.04 1.01 0.74 0.66 0.64
Receivable days arrow
296.65 87.83 85.17 132.12 132.49
Inventory Days arrow
15.72 78.64 90.97 102.08 68.07
Payable days arrow
190.57 174.97 137.94 133.54 123.94
Cash Conversion Cycle arrow
121.80 -8.50 38.21 100.66 76.63
loading...
loading...
loading...